KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancerПодробнее

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBCПодробнее

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast CancerПодробнее

KEYNOTE-522: Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs place...Подробнее

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBCПодробнее

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...Подробнее

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBCПодробнее

Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBCПодробнее

KEYNOTE-522: Immune therapy and chemotherapy in patients with early triple negative breast cancerПодробнее

Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & moreПодробнее

Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522Подробнее

Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)Подробнее

KEYNOTE-522: EFS sensitivity & subgroup analysesПодробнее

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBCПодробнее

GS1-01: "Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant..."Подробнее

Early TNBC - Pembrolizumab + chemotherapy: Pathologic complete response in key subgroupsПодробнее

The case for neoadjuvant pembrolizumab in TNBCПодробнее

A post hoc analysis of adjuvant radiation therapy in the KEYNOTE-522 studyПодробнее

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OSПодробнее